papillary thyroid cancer semaglutide papillary thyroid carcinoma - GLP-1 afterpapillary thyroid cancer papillary thyroid cancer Examining the Link: Papillary Thyroid Cancer and Semaglutide

GLP-1 afterpapillary thyroid cancer The emergence of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist widely recognized for its efficacy in managing type 2 diabetes and promoting weight loss, has also sparked discussions regarding its potential association with thyroid cancer, particularly papillary thyroid carcinomaAssessment of Thyroid Carcinogenic Risk and Safety Profile of .... While initial animal studies raised concerns, a growing body of human research and clinical observations is providing a clearer, albeit nuanced, picture2025年4月7日—Having a history ofpapillary thyroid cancerdoes not automatically disqualify you from taking Ozempic (semaglutide), as the FDA warning .... This article delves into the current understanding of the relationship between semaglutide and papillary thyroid cancer, drawing upon scientific findings and expert interpretations to offer insights for patients and healthcare providers.

Recent studies have investigated the incidence of thyroid cancer among patients using semaglutide and other GLP-1 receptor agonists (GLP-1RAs)2025年6月4日—That study reported a 58% increased risk ofthyroid cancerwith exposure to GLP-1RAs for 1–3 years, and a 36% increased risk with exposure >3 .... One notable finding indicates that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant increase in risk. This aligns with broader research on GLP-1RAs, where metaanalyses have shown no increased risk for differentiated thyroid cancer. In fact, some findings suggest that semaglutide does not promote thyroid cancer and may even offer benefits by reprogramming macrophages, potentially leading to semaglutide may improve therapeutic strategies for conditions affecting the thyroid.

However, it is crucial to acknowledge the complexity of this relationship作者：CVI Feier·2024·被引用次数：79—The incidence of thyroid cancer in semaglutide-treated patients wasless than 1%, suggesting no significant risk. Adverse events were .... While large-scale studies often demonstrate a low incidence, individual case reports have emerged, such as a presentation of rapidly progressive PTC in a patient shortly after initiating semaglutide for weight loss. These isolated instances, though rare, warrant careful consideration.Who Should Not Take Mounjaro? Experts Explain - GoodRx It's important to distinguish between different types of thyroid tumors; while human evidence is lacking for papillary, follicular, or Oncocytic (Hürthle cell) thyroid cancers being caused by GLP-1 receptor agonists, some animal research does suggest that semaglutide can increase the risk of developing thyroid C-cell tumours. This distinction is vital, especially when considering conditions like medullary thyroid cancer, for which GLP-1 agents may be contraindicated in individuals with a personal or family history.

The FDA warning regarding semaglutide and thyroid tumors mentions a potential link, but it's essential to understand that this doesn't automatically disqualify individuals with a history of papillary thyroid cancer from taking semaglutide2025年4月7日—Having a history ofpapillary thyroid cancerdoes not automatically disqualify you from taking Ozempic (semaglutide), as the FDA warning .... Some sources indicate that Wegovy (semaglutide) is not contraindicated for papillary thyroid carcinoma, although caution is advised for those with a personal or family history of thyroid conditions. The medical community generally advises caution when prescribing GLP-1 agents to patients with a genetic predisposition for papillary or follicular thyroid cancer, or those with a history of thyroid cancer.

Further research is ongoing to fully elucidate how semaglutide influences the progression of TC (Thyroid Carcinoma). Some studies indicate a relatively low incidence of thyroid cancer among patients with thyroid nodules treated with GLP-1 analogues. Conversely, other research has reported an increased risk of all thyroid cancer with the use of GLP-1 RAs, particularly after prolonged use (1-3 years). This highlights the need for continued monitoring and personalized risk assessment.Exploring Connections Between Weight‐Loss Medications ...

For individuals undergoing treatment with semaglutide, open communication with their healthcare provider is paramount. Understanding the nuances of semaglutide causes thyroid tumors is an ongoing scientific endeavor.Should we be concerned about thyroid cancer in patients ... While "no incidence to date of semaglutide causing any kind of thyroid cancer in humans" is a reassuring statement from some perspectives, the existence of conflicting or cautionary data necessitates a vigilant approachRapid Progression of Papillary Thyroid Carcinoma .... Ultimately, the decision to use semaglutide, or its brand names like Wegovy (semaglutide), should be a shared one, weighing the significant benefits for diabetes and weight management against the potential, albeit generally low and still debated, risks associated with thyroid cancer2024年9月5日—While researchers have foundno incidence to date of semaglutide causing any kind of thyroid cancerin humans, the earliest laboratory research .... Patients with a history of papillary thyroid cancer should engage in thorough discussions with their endocrinologist or oncologist to make informed choices.